Lift-Off Time For LipiScan? Data And Payment Policies Will Tell
This article was originally published in The Pink Sheet Daily
Executive Summary
A randomized trial will measure the catheter-based system's ability to pick patients vulnerable to MI during stenting, but regardless of the data collection or the available technology, a major barrier standing in the way of LipiScan adoption is reimbursement.
You may also be interested in...
Four Device Makers Apply For 2011 New-Technology Add-On Bonus
CMS has received five applications from four device firms for its next round of new-technology add-on payments, including submissions for two products that did not qualify for the extra payment during previous attempts
Volcano Takes Advantage Of Competitors' Trials To Tout FFR, IVUS
Intravascular imaging device-maker Volcano is talking up the results of two trials presented at the TCT conference, although it was not the primary sponsor of either of them
InfraReDx Launches LipiScan To Evaluate Coronary Plaque
InfraReDx is launching its catheter-based LipiScan coronary imaging system, which relies upon near-infrared spectroscopy to identify plaque most likely to cause heart attacks and death, following April 25 FDA 510(k) clearance of the device